Technical Analysis for ALDX - Aldeyra Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | -2.72% | |
| Bollinger Band Squeeze | Range Contraction | -2.72% | |
| NR7 | Range Contraction | -2.72% | |
| Inside Day | Range Contraction | -2.72% | |
| 20 DMA Support | Bullish | -5.05% | |
| Bollinger Band Squeeze | Range Contraction | -5.05% | |
| Bollinger Band Squeeze | Range Contraction | -3.90% | |
| Inside Day | Range Contraction | -3.90% | |
| 20 DMA Support | Bullish | -4.82% | |
| Spinning Top | Other | -4.82% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| Down 1% | about 4 hours ago |
| Fell Below 20 DMA | about 4 hours ago |
| 20 DMA Support | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Disease Organ Systems Autoimmune Disease Rare Diseases Dysfunction Lupus Syndromes Inflammatory Uveitis Rosacea Systemic Lupus Erythematosus Discoid Lupus Meibomian Gland Ns2
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Disease Organ Systems Autoimmune Disease Rare Diseases Dysfunction Lupus Syndromes Inflammatory Uveitis Rosacea Systemic Lupus Erythematosus Discoid Lupus Meibomian Gland Ns2
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.97 |
| 52 Week Low | 1.42 |
| Average Volume | 615,386 |
| 200-Day Moving Average | 4.29 |
| 50-Day Moving Average | 3.73 |
| 20-Day Moving Average | 4.05 |
| 10-Day Moving Average | 4.08 |
| Average True Range | 0.24 |
| RSI (14) | 53.70 |
| ADX | 29.97 |
| +DI | 25.78 |
| -DI | 12.98 |
| Chandelier Exit (Long, 3 ATRs) | 3.97 |
| Chandelier Exit (Short, 3 ATRs) | 4.50 |
| Upper Bollinger Bands | 4.34 |
| Lower Bollinger Band | 3.76 |
| Percent B (%b) | 0.53 |
| BandWidth | 14.28 |
| MACD Line | 0.10 |
| MACD Signal Line | 0.12 |
| MACD Histogram | -0.0131 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.25 | ||||
| Resistance 3 (R3) | 4.26 | 4.21 | 4.22 | ||
| Resistance 2 (R2) | 4.21 | 4.17 | 4.21 | 4.21 | |
| Resistance 1 (R1) | 4.14 | 4.14 | 4.12 | 4.13 | 4.20 |
| Pivot Point | 4.09 | 4.09 | 4.08 | 4.09 | 4.09 |
| Support 1 (S1) | 4.02 | 4.05 | 4.00 | 4.01 | 3.94 |
| Support 2 (S2) | 3.97 | 4.02 | 3.97 | 3.93 | |
| Support 3 (S3) | 3.90 | 3.97 | 3.92 | ||
| Support 4 (S4) | 3.89 |
